[Comparison of bicyclol therapy for patients with genotype B and C of hepatitis B virus].
OBJECTIVE
To compare the efficacy of bicyclol tablets on patients infected with hepatitis B virus between genotype B and C.


METHODS
70 patients with chronic viral hepatitis B were selected. The patients divide into two groups: HBV genotypes B (26 cases) and HBV genotypes C (other 44 cases). All patients received bicyclol tablets orally 150 mg daily (50mg, tid, po) for 24 weeks. The efficacy were observed after 12 weeks and 24 weeks.


RESULTS
After treatment for 24 weeks, the serum aminotransferase were decreased obviously, and HBV DNA levels turn to be negative with 19.2 percent (genotype B group) and 15.9 percent (genotype C group), respectively. The difference was not statistically significant between HBV genotype B and C.


CONCLUSIONS
Bicyclol not only has hepatoprotective activity but also inhibited virus replication in patients infected with HBV. The difference of the response to bicyclol therapy between HBV genotypes B and C was not statistically significant.
Ruan
Bing
B
First Affiliated Hospital; Medical College of Zhejiang University, Zhejiang 310003, China. ruanbing@zjwst.gov.cn
Wang
Jun-wei
JW
Bai
Xue-ling
XL
D000293:Adolescent; D000328:Adult; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D006515:Hepatitis B virus / Q000145:classification*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged
D001713:Biphenyl Compounds; C477843:bicyclol